Treatment of uncomplicated gonococcal urethritis in men with two dosages of ciprofloxacin
Articles Ciprofloxacin: Clinical Experience
One hundred and sixty-four male patients suffering from urethral gonorrhoea were treated in an open randomised trial with either 250 mg (n=85) or 500 mg (n=79) ciprofloxacin administered in one tablet. Cure rates in both groups were 100%. Postgonococcal urethritis was observed in 31 of 85 (36%) patients in the first group, and in 21 of 79 patients (27%) in the second group. Side-effects were minor, occurring in four patients in the 250 mg group (4.7%) and in seven in the 500 mg group (8.9%). The side-effects consisted of nausea, diarrhoea and headache. Ciprofloxacin would appear to be a very effective drug in the treatment of urethral gonorrhoea in males.
KeywordsInternal Medicine Male Patient Randomise Trial Effective Drug Urethritis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Klingeren, B. van, Wijngaarden, J. L. van, Dessens-Kroon, M., Embden, J. D. A.
: Penicillinase-producing gonococcal in the Netherlands in 1981. Journal of Antimicrobial Chemotherapy 1981, 11: 15–20.Google Scholar
Nayyar, K. C., Noble, R. C., Michel, M. F., Stolz, E.
: Gonorrhoea in Rotterdam caused by penicillinase-producing gonococci. British Journal of Venereal Diseases 1980, 56: 244–248.PubMedGoogle Scholar
Nayyar, K. C., Michel, M. F., Stolz, E.
: Antibiotic sensitivities of gonococci isolated in Rotterdam and results of treatment with cefuroxime. British Journal of Venereal Diseases 1980, 56: 249–251.PubMedGoogle Scholar
Wise, R., Andrews, J. M., Edwards, L. J.
: In vitro activity of Bay 09867, a new quinolone derivative compared with those of other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1983, 23: 559–564.PubMedGoogle Scholar
Peeters, M., van Dyck, E., Piot, P.
: In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives againstNeisseria gonorrhoeae
. Antimicrobial Agents and Chemotherapy 1984, 26: 608–609.PubMedGoogle Scholar
Crump, B., Wise, R., Dent, J.
: Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1983, 24: 784–786.PubMedGoogle Scholar
Wingerden, W., Graefe, K. H., Gau, W., Förster, D., Beermann, D., Schacht, P.
: Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. European Journal of Clinical Microbiology 1984, 3: 355–359.CrossRefPubMedGoogle Scholar
Loo, P. S., Ridgway, G. L., Oriel, J. D.
: Single dose ciprofloxacin for treating gonococcal infections in men. Genitourinary Medicine 1985, 61: 302–305.PubMedGoogle Scholar
Stolz, E., Ong, L., van Joost, R., Michel, M. F.
: Treatment of non-complicated urogenital, rectal and oropharyngeal gonorrhoea with intramuscular cefotaxime 1.0 g or cefuroxime 1.5 g. Journal of Antimicrobial Chemotherapy 1984, 14: 295–299.PubMedGoogle Scholar
© Friedr. Vieweg & Sohn 1986